1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Keloid Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Keloid Treatment Market, by Product Type
8.1.1 Topical Products (Gels, Sheets)
8.1.1.1. Market Revenue and Forecast
8.1.2. Injectable Products
8.1.2.1. Market Revenue and Forecast
8.1.3. Laser and Energy-based Devices
8.1.3.1. Market Revenue and Forecast
8.1.4. Others (Cryotherapy/Radiation)
8.1.4.1. Market Revenue and Forecast
9.1. Keloid Treatment Market, by Treatment Type
9.1.1. Intralesional Corticosteroids
9.1.1.1. Market Revenue and Forecast
9.1.2. Laser Therapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Surgical Excision
9.1.3.1. Market Revenue and Forecast
9.1.4. Radiation and Cryosurgery
9.1.4.1. Market Revenue and Forecast
10.1. Keloid Treatment Market, by End-User
10.1.1. Hospitals and Specialized Clinics
10.1.1.1. Market Revenue and Forecast
10.1.2. Dermatology Centers
10.1.2.1. Market Revenue and Forecast
10.1.3. Homecare/E-commerce
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product Type
11.1.2. Market Revenue and Forecast, by Treatment Type
11.1.3. Market Revenue and Forecast, by End-User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product Type
11.1.4.2. Market Revenue and Forecast, by Treatment Type
11.1.4.3. Market Revenue and Forecast, by End-User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product Type
11.1.5.2. Market Revenue and Forecast, by Treatment Type
11.1.5.3. Market Revenue and Forecast, by End-User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product Type
11.2.2. Market Revenue and Forecast, by Treatment Type
11.2.3. Market Revenue and Forecast, by End-User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product Type
11.2.4.2. Market Revenue and Forecast, by Treatment Type
11.2.4.3. Market Revenue and Forecast, by End-User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product Type
11.2.5.2. Market Revenue and Forecast, by Treatment Type
11.2.5.3. Market Revenue and Forecast, by End-User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product Type
11.2.6.2. Market Revenue and Forecast, by Treatment Type
11.2.6.3. Market Revenue and Forecast, by End-User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product Type
11.2.7.2. Market Revenue and Forecast, by Treatment Type
11.2.7.3. Market Revenue and Forecast, by End-User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product Type
11.3.2. Market Revenue and Forecast, by Treatment Type
11.3.3. Market Revenue and Forecast, by End-User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product Type
11.3.4.2. Market Revenue and Forecast, by Treatment Type
11.3.4.3. Market Revenue and Forecast, by End-User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product Type
11.3.5.2. Market Revenue and Forecast, by Treatment Type
11.3.5.3. Market Revenue and Forecast, by End-User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product Type
11.3.6.2. Market Revenue and Forecast, by Treatment Type
11.3.6.3. Market Revenue and Forecast, by End-User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product Type
11.3.7.2. Market Revenue and Forecast, by Treatment Type
11.3.7.3. Market Revenue and Forecast, by End-User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product Type
11.4.2. Market Revenue and Forecast, by Treatment Type
11.4.3. Market Revenue and Forecast, by End-User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product Type
11.4.4.2. Market Revenue and Forecast, by Treatment Type
11.4.4.3. Market Revenue and Forecast, by End-User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product Type
11.4.5.2. Market Revenue and Forecast, by Treatment Type
11.4.5.3. Market Revenue and Forecast, by End-User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product Type
11.4.6.2. Market Revenue and Forecast, by Treatment Type
11.4.6.3. Market Revenue and Forecast, by End-User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product Type
11.4.7.2. Market Revenue and Forecast, by Treatment Type
11.4.7.3. Market Revenue and Forecast, by End-User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product Type
11.5.2. Market Revenue and Forecast, by Treatment Type
11.5.3. Market Revenue and Forecast, by End-User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product Type
11.5.4.2. Market Revenue and Forecast, by Treatment Type
11.5.4.3. Market Revenue and Forecast, by End-User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product Type
11.5.5.2. Market Revenue and Forecast, by Treatment Type
11.5.5.3. Market Revenue and Forecast, by End-User
12.1. Alliance Pharma plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Avita Medical
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bausch Health Companies (Valeant)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Candela Medical
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Cynosure, LLC
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Lumenis (Boston Scientific/BPEA)
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merz Pharma GmbH and Co. KGaA
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Mölnlycke Health Care AB
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Newmedical Technology, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pacific World Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
